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Materials. Fmoc-β-alanine-p-benzyloxybenzyl alcohol resin (Fmoc-β-Wang-
resin), 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate
(HBTU), and Boc-γ-Aminobutyric Acid were purchased from Peptides International.
N,N-Diisopropylethylamine (DIEA), piperidine, and N-methylpyrrolidone (NMP), were
purchased from Applied Biosystems. Dichloromethane (DCM) and triethylamine (TEA)
were reagent grade from EM, 9-Fluorenylmethyl chloroformate (Fmoc-Cl), thiophenol
(PhSH), (dimethylamino)propylamine, trichloroacetylchloride, N-methylpyrrole, and N-
methylimidazole were from Aldrich, and trifluoroacetic acid (TFA) was from
Halocarbon. All reagents were used without further purification.
1H NMR spectra were recorded on a General Electric-QE NMR spectrometer at
300 MHz in DMSO-d6, with chemical shifts reported in parts per million relative to
residual solvent.  UV spectra were measured in water on a Hewlett-Packard Model
8452A diode array spectrophotometer.  Matrix-assisted, laser desorption/ionization time
of flight mass spectrometry (MALDI-TOF) electrospray mass spectrometry were
performed at the Protein and Peptide Microanalytical Facility at the California Institute of
Technology.  HPLC analysis was performed on either on a HP 1090M analytical HPLC
or a Beckman Gold system using a RAINEN C18,  Microsorb MV, 5µm, 300 x 4.6 mm
reversed phase column in 0.1% (wt/v) TFA with acetonitrile as eluent and a flow rate of
1.0 mL/min, gradient elution 1.25% acetonitrile/min.  Preparatory reversed phase HPLC
was performed on a Beckman HPLC with a Waters DeltaPak 25 x 100 mm, 100 µm C18
column equipped with a guard, 0.1% (wt/v) TFA, 8.0 ml/min, 0.25% acetonitrile/min.
18MW water was obtained from a Millipore MilliQ water purification system, and all
buffers were 0.2 µm filtered.
Monomer Synthesis.
tert-Butyl 4-Nitro-1-methylpyrrole-2-carboxylate (5a). To a suspension of 4-nitro-2-
(trichloroacetyl)-1-methylpyrrole (5a) (50 g, 19.5 mmol) in 500 ml of tert-butyl alcohol
was added sodium tert-butoxide (25 g) over 1 hour.  The suspension was refluxed under
argon for 5 hours.  The mixture was quenched with 500 ml of water and extracted with
chloroform (3 × 500 ml).  The chloroform was concentrated in vacuo to provide 6a (39.4
g, 94.6% yield).  TLC (3:1 hexanes: ethyl acetate) Rf 0.52  1H NMR (DMSO-d6) δ 8.18 (d,
1 H, J = 2.4), 7.18 (d, 1 H, J = 2.4), 3.97 (s, 3 H), 1.47 (s, 9 H). FABMS m/e 226.096
(226.095 calcd for C10H14N2O4).
tert-Butyl 4-[(9-Fluorenylmethoxycarbonyl)amino]-1-methylpyrrole-2-
carboxylate (6a). To a solution of tert-Butyl 4-Nitro-1-methylpyrrole-2-carboxylate (5a)
(20.0 g, 88.4 mmol) in 100 ml of DMF was added 10% Pd/C (2 g) in 20 ml of DMF. The
mixture was vigorously stirred for 2 h under 500 psi of hydrogen, filtered though Celite,
and the Celite was washed with DMF (1 × 200 ml). The two filtrates were combined,
Fmoc-Cl (25.3 g, 92.8 mmol) and DIEA (35 ml, 200 mmol) were added and the solution
was stirred for 10 hours. Water (250 ml) was added, and the mixture extracted with ethyl
ether (2 × 500 ml).  The  ether was dried (sodium sulfate) and concentrated in vacuo to
~200 ml. Hexanes was added to preciptitate a brown solid which was washed with cold
methanol/H20 to yield 6a as a white solid (24.3 g, 66% yield). TLC (3:1 hexanes/ethyl
acetate) Rf 0.39   1H NMR (DMSO-d6) δ 9.45 (s, 1 H), 7.92 (m, 2 H), 7.71 (m, 2 H), 7.44
(m, 2 H), 7.36 (m, 2 H), 7.03 (d, 1 H, J = 2.4), 6.63 (d, 1 H, J = 2.4), 4.45 (d, 2 H, J =
6.3), 4.31 (t, 1 H, J = 6.3),  3.78 (s, 3 H), 1.50 (s, 9 H). FABMS m/e 418.189 (418.189
calcd for C25H26N2O4).
4-[(9-Fluorenylmethoxycarbonyl)amino]-1-methylpyrrole-2-carboxylic acid
(8a). tert-Butyl 4-[(9-Fluorenylmethoxycarbonyl)amino]-1-methylpyrrole-2-carboxylate
(7a) (5.0 g, 12.0 mmol) was dissolved in 100 ml of dichloromethane and cooled to 0° C.
TiCl4 (25 ml, 1.0 M in dichloromethane) was added dropwise to the solution.  The
mixture was stirred for 30 min.  1 M HCl (250 ml) was cooled to 4°C and added
dropwise. The resulting  white precipitate (8a) was collected by vacuum filtration and
washed with a small amount of cold water and dried in vacuo (3.8 g, 88% yield). TLC
(1:1 hexanes/ethyl acetate) Rf 0.15    1H NMR (DMSO-d6) δ 12.16 (bs, 1 H), 9.45 (s, 1 H),
7.92 (m, 2 H), 7.74 (m, 2 H), 7.44 (m, 2 H), 7.36 (m, 2 H), 7.07 (d, 1 H, J = 2.4), 6.64 (d,
1 H, J = 2.4), 4.46 (d, 2 H, J = 6.3), 4.30 (t, 1 H, J = 6.3),  3.80 (s, 3 H). FABMS m/e
362.127 (362.126 calcd for C21H18N2O4).
4-Nitro-2-(trichloroacetyl)-1-methylimidazole (3b).  A solution of 2-
(tricholoroacteyl)-1-methylimidazole (700 g, 3.1 mol) in 4 L of acetic anhydride was
cooled to -40° C.  Fuming nitric acid (500 ml), followed by conc. sulfuric acid (25 ml)
was added over 2 h, and the reaction mixture was stirred for 12 hours.  The mixture was
poured into a tray and allowed to crystallize over two days.  The product was collected by
vacuum filtration, washed (cold water, 1 × 100 ml), and dried in vacuo to yield 4b as a
white crystalline solid (472 g, 56 % yield).  TLC (1:1 hexanes/ethyl acetate) Rf 0.57  1H
NMR (DMSO-d6) δ  8.84 (s, 1 H), 4.04 (s, 3 H).  FABMS m/e 270.932 (270.932 calcd
for C6H4N3O3).
tert-Butyl 4-Nitro-1-methylimidazole-2-carboxylate (4b).  To a mixture of 4-
nitro-2-(trichloroacetyl)-1-methylimidazole (5b) (50 g, 0.18 mol) in 500 ml of tert-butyl
alcohol was added sodium tert-butoxide (20 g) over 1 hour.  The reaction was refluxed
under argon for 5 hours, then quenched with 500 ml of water and extracted with
chloroform (3 × 500 ml).  The chloroform was removed in vacuo to provide 6b (36.4 g,
84% yield). TLC (1:1 hexanes/ethyl acetate) Rf 0.59  1H NMR (DMSO-d6) δ  8.62 (s, 1
H), 3.98 (s, 3 H), 1.58 (s, 9 H).  FABMS m/e 227.091 (227.091 calcd for C9H13N3O4).
tert-Butyl 4-[(9-Fluorenylmethoxycarbonyl)amino]-1-methylimidazole-2-
carboxylate (6b). tert-Butyl 4-Nitro-1-methylimidazole-2-carboxylate (6b) (9.2 g, 40
mmol) was dissolved in 100 ml of DMF. 10% Pd/C (1 g) in 20 ml of DMF was added.
The mixture was vigorously stirred for 2 h under 500 psi of Hydrogen and then filtered
though Celite.  The Celite was rinsed with DMF (200 ml). Fmoc-Cl (10.7 g, 41 mmol)
was added and the solution was stirred for 3 hour.   Water was added to the DMF and the
mixture was extracted with diethyl ether.  The ether was extracted 2 × water and 1 ×
brine, dried over sodium sulfate and concentrated by rotoevaporation to yield a crude
yellow solid which was dissolved in a minimum amount of diethyl ether. Purified by
column chromatography (3:1 hexanes/ethyl acetate, 5.9 g, 34.4% yield). TLC (1:1
hexanes/ethyl acetate) Rf 0.64  1H NMR (DMSO-d6) δ  10.4 (s, 1 H), 7.9 (d, 2 H), 7.7 (d, 2
H), 7.4 (m, 2 H), 7.3 (m, 2 H), 7.2 (s, 1H), ), 4.4 (d, 2 H, J = 6), 4.3 (t, 1 H, J = 6), 3.9 (s,
3 H), 1.6 (s, 9 H). FABMS m/e 419.185 (419.184 calcd for C24H25N3O4).
4-[(9-Fluorenylmethoxycarbonyl)amino]-1-methylimidazole-2-carboxylic
Acid (7b). tert-Butyl 4-[(9-Fluorenylmethoxycarbonyl)amino]-1-methylimidazole-2-
carboxylate (7b) (5.0 g, 11.9 mmol) was dissolved in 100 ml of dichloromethane and
cooled to 0° C. TiCl4 (25 ml, 1.0 M in dichloromethane) was added dropwise to the
solution.  The mixture was stirred for 1 hour.  Cold HCl (1 M, 500 ml) was added.  The
white precipitate was collected by vacuum filtration (3.7 g, 86% yield). 1H NMR
(DMSO-d6) δ  12.4 (bs, 1 H), 10.4 (s, 1 H), 7.9 (d, 2 H), 7.7 (d, 2 H), 7.4 (m, 2 H), 7.3
(m, 2 H), 7.2 (s, 1H), ), 4.4 (d, 2 H, J = 6), 4.3 (t, 1 H, J = 6), 3.9 (s, 3 H).  FABMS m/e
364.131 (M+H) (364.122 calcd for C20H17N3O4).
Solid Phase Synthesis. Activation of Fmoc-Imidazole Acid. Activation of
Imidazole-2-carboxylic acid, Fmoc-Pyrrole acid, Fmoc-Imidazole acid and γ-
aminobutyric acid. The appropriate amino acid or acid (2 mmol) was dissolved in 2 mL
of DMF.  HBTU (720 mg, 1.9 mmol) was added followed by DIEA (1 mL) and the
solution was lightly shaken for at least 5 min.
Machine-Assisted Protocols. Machine-assisted synthesis was performed on an
ABI 430A synthesizer on a 0.69 mmol scale (800 mg resin; 0.86 mmol/g). Each cycle of
amino acid addition involved deprotection with approximately 80% Piperidine/NMP for
3 min, draining the reaction vessel, and then deprotection for 17 min; two NMP washes; a
DCM wash; an NMP wash; draining the reaction vessel; coupling for 1 h (8 h when
coupling to imidazole), addition of dimethyl sulfoxide (DMSO)/NMP, coupling for 30
min; draining the reaction vessel; washing with DCM, taking a resin sample for
evaluation of the progress of the synthesis for HPLC analysis; capping with acetic
anhydride/DIEA in DCM for 6 min; and washing with DCM.
The ABI 430A synthesizer was left in the standard hardware configuration for
NMP-HOBt protocols. Reagent position 1 was piperidine, reagent position 2 was not
used, reagent position 3 was 70% ethanolamine/methanol, reagent position 4 was acetic
anhydride, reagent position 5 was DMSO/NMP, reagent position 6 was methanol, reagent
position 7 was DIEA, and reagent position 8 was NMP.
Fmoc-Im acid was added manually. Fmoc-imidazole acid (363 mg, 1 mmol) and
HBTU (378 mg, 1 mmol) were combined in 2 mL of NMP.  DIEA (1 ml) was then
added, and the reaction mixture was allowed to stand for 5 min. At the initiation of the
coupling cycle the synthesis was interrupted, the reaction vessel vented, and the activated
monomer added directly to the reaction vessel. When manual addition was necessary, an
empty synthesis cartridge was used.
Fmoc-Py acid (362 mg, 1 mmol) and aliphatic amino acids (2 mmol) were placed
in a synthesis cartridge with 0.9 equiv. HBTU. NMP (3 ml) was added using a calibrated
delivery loop from reagent bottle 8, followed by a calibrated delivery of 1 mL of DIEA
from reagent bottle 7, and a 3 min mixing of the cartridge.
The activator cycle was written to transfer activated monomer directly from the
cartridge to the concentrator vessel, bypassing the activator vessel. After transfer, 1 mL
of DIEA was measured into the cartridge using a calibrated delivery loop, and the DIEA
solution was combined with the activated monomer solution in the concentrator vessel.
The activated ester in 2:1 DMF/DIEA was then transferred to the reaction vessel. All
lines were emptied with argon before and after solution transfers.
ImPyPyPy-γ-PyPyPyPy-β-Dp (1). ImPyPyPy-γ-PyPyPyPy-β-Wang resin was
prepared by machine-assisted synthesis protocols. A sample of resin (1 g, 0.47 mmol/g)
was placed in a 20 mL glass scintillation vial. 4 mL of N,N-(dimethylamino) propylamine
added, and the solution heated at 55 °C for 18 h. Resin was removed by filtration through
a disposable propylene filter, and 16 mL of water was added. The polyamide/amine
mixture was purified directly by preparatory HPLC, and the appropriate fractions were
lyophilized to provide the trifluoroacetate salt of ImPyPyPy-γ-PyPyPyPy-β-Dp (240 mg,
38% recovery) as a white powder. MALDI-TOF-MS (monoisotopic), 1221.5 (1221.6
calc. for M+H).
ImPyPyPy-γ-ImPyPyPy-β-Dp (2). ImPyPyPy-γ-PyPyPyPy-β-Wang resin was
prepared by machine-assisted synthesis protocols. A sample of resin (1 g, 0.47 mmol/g)
was placed in a 20 mL glass scintillation vial. 4 mL of (dimethylamino)propylamine
added, and the solution heated at 55 °C for 18 h. Resin was removed by filtration through
a disposable propylene filter, and 16 mL of water was added. The polyamide/amine
mixture was purified directly by preparatory HPLC, and the appropriate fractions were
lyophilized to provide the trifluoroacetate salt of ImPyPyPy-γ-ImPyPyPy-β-Dp (57 mg,
9% recovery) as a white powder. MALDI-TOF-MS (monoisotopic), 1222.5 (1222.6 calc.
for M+H).
Stepwise HPLC Analysis. A resin sample (ca. 4 mg) was placed in a 4 mL glass
test tube. 200 mL of (N,N-dimethylamino)propylamine was added, and the mixture was
heated at 100 °C for 5 min. The cleavage mixture was filtered and a 25 mL sample
analyzed by analytical HPLC at 254 nm.
